Show simple item record

dc.contributor.authorGbolade, B
dc.contributor.authorEllis, S
dc.contributor.authorMurby, Brian
dc.contributor.authorRandall, S
dc.contributor.authorKirkman, R
dc.date.accessioned2010-02-12T12:27:41Z
dc.date.available2010-02-12T12:27:41Z
dc.date.issued1998-07
dc.identifier.citationBone density in long term users of depot medroxyprogesterone acetate. 1998, 105 (7):790-4 Br J Obstet Gynaecolen
dc.identifier.issn0306-5456
dc.identifier.pmid9692421
dc.identifier.urihttp://hdl.handle.net/10541/91974
dc.description.abstractOBJECTIVE: To identify any adverse effect on bone density in long term users of depot medroxyprogesterone acetate (DMPA) for contraception. DESIGN: Cross-sectional measurement of bone density in users with amenorrhoea of more than one year or any woman using DMPA for more than five years. SETTING: Community Family Planning Clinics in Portsmouth and Manchester. POPULATION: One hundred and eighty-five women aged 17-52 years (mean 33.3 years) who had used DMPA for between 1 and 16 years and were attending the clinics for further injections, between August 1994 and August 1996. METHODS: Dual energy X-ray measurement of bone density of femoral neck and lumbar spine, and venous blood sample taken just prior to the next injection of DMPA. MAIN OUTCOME MEASURES: Bone density of femoral neck and lumbar spine and serum oestradiol in relationship to years of DMPA use and duration of amenorrhoea. RESULTS: Most women (n=153) had serum oestradiol levels < 150 pmol/l. Despite this, the mean bone density of the lumbar spine compared with the population mean for women aged 20-59 years gave a Z score (95% CI) of -0.332 (-0.510 to -0.154). There was no significant difference in the mean density of the femoral neck from the normal population mean. CONCLUSION: Despite amenorrhoea and low serum oestradiol, this sample of long term DMPA users had bone density only minimally below the normal population mean. We therefore found no clinically important adverse effect on bone density and therefore no reason to recommend bone conserving measures, such as add-back oestrogen.
dc.language.isoenen
dc.subject.meshAdolescent
dc.subject.meshAdult
dc.subject.meshBone Density
dc.subject.meshContraceptive Agents, Female
dc.subject.meshCross-Sectional Studies
dc.subject.meshFemale
dc.subject.meshFemur Neck
dc.subject.meshHumans
dc.subject.meshLumbar Vertebrae
dc.subject.meshMedroxyprogesterone Acetate
dc.subject.meshMiddle Aged
dc.subject.meshTime Factors
dc.titleBone density in long term users of depot medroxyprogesterone acetate.en
dc.typeArticleen
dc.contributor.departmentPalatine Centre, University of Manchester, UK.en
dc.identifier.journalBritish Journal of Obstetrics and Gynaecologyen
html.description.abstractOBJECTIVE: To identify any adverse effect on bone density in long term users of depot medroxyprogesterone acetate (DMPA) for contraception. DESIGN: Cross-sectional measurement of bone density in users with amenorrhoea of more than one year or any woman using DMPA for more than five years. SETTING: Community Family Planning Clinics in Portsmouth and Manchester. POPULATION: One hundred and eighty-five women aged 17-52 years (mean 33.3 years) who had used DMPA for between 1 and 16 years and were attending the clinics for further injections, between August 1994 and August 1996. METHODS: Dual energy X-ray measurement of bone density of femoral neck and lumbar spine, and venous blood sample taken just prior to the next injection of DMPA. MAIN OUTCOME MEASURES: Bone density of femoral neck and lumbar spine and serum oestradiol in relationship to years of DMPA use and duration of amenorrhoea. RESULTS: Most women (n=153) had serum oestradiol levels < 150 pmol/l. Despite this, the mean bone density of the lumbar spine compared with the population mean for women aged 20-59 years gave a Z score (95% CI) of -0.332 (-0.510 to -0.154). There was no significant difference in the mean density of the femoral neck from the normal population mean. CONCLUSION: Despite amenorrhoea and low serum oestradiol, this sample of long term DMPA users had bone density only minimally below the normal population mean. We therefore found no clinically important adverse effect on bone density and therefore no reason to recommend bone conserving measures, such as add-back oestrogen.


This item appears in the following Collection(s)

Show simple item record